Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
3(21%)
Results Posted
50%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
3
21%
Ph phase_3
3
21%
Ph phase_1
2
14%
Ph phase_4
6
43%

Phase Distribution

2

Early Stage

3

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
3(21.4%)
Phase 3Large-scale testing
3(21.4%)
Phase 4Post-market surveillance
6(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

14

all time

Status Distribution
Active(3)
Completed(10)
Terminated(1)

Detailed Status

Completed10
Recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
3
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 23 (21.4%)
Phase 33 (21.4%)
Phase 46 (42.9%)

Trials by Status

completed1071%
terminated17%
recruiting321%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT07412470Phase 2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Recruiting
NCT04375631Phase 1

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recruiting
NCT04195633Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting
NCT02334488Phase 3

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Completed
NCT00574197Phase 4

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Completed
NCT02953873Phase 4

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

Completed
NCT01801280Phase 4

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Completed
NCT01410448Phase 3

Everolimus in de Novo Kidney Transplant Recipients

Completed
NCT00646737Phase 4

Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

Completed
NCT01822483Phase 4

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)

Completed
NCT01354301Phase 4

Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate

Completed
NCT01015456Phase 3

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Terminated
NCT00423098Phase 2

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Completed
NCT00542763Phase 1

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14